Roche Diagnostics Boosts Staff To Focus On Medical Genomics Research
This article was originally published in The Gray Sheet
Executive Summary
Roche Diagnostics will bolster its genetic research efforts by adding a 100-person genomics staff as it seeks to capitalize on advances being made in the genomics field by shifting its R&D focus from clinical chemistry to molecular genetics.
You may also be interested in...
MiniMed To File Home-Use Continuous Glucose Monitor PMA In Early 2000
MiniMed is developing a follow-on version of its continuous glucose monitoring system (CGMS) that will be sold directly to patients, allowing them to monitor their own glucose levels, the firm said following FDA's June 16 approval of a non-consumer configuration as an adjunct to finger-stick blood glucose testing.
Roche Cedes CEDIA DOA Reagents, Seals Corange Deal March 5
Roche is negotiating with potential buyers of Boehringer Mannheim's Closed Enzyme Donor Immuno Assay (CEDIA) reagents for drugs-of-abuse (DOA) testing to comply with conditions of a Feb. 24 Federal Trade Commission settlement. The FTC settlement cleared the way for Roche's $10.2 bil. acquisition of Corange, the parent company of Boehringer Mannheim and DePuy.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”